{"id":795254,"date":"2024-12-16T16:34:43","date_gmt":"2024-12-16T21:34:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/"},"modified":"2024-12-16T16:34:43","modified_gmt":"2024-12-16T21:34:43","slug":"tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/","title":{"rendered":"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024"},"content":{"rendered":"

\nCompany to host conference call on Tuesday, December 17, at 8:00 a.m. ET
\n<\/h2>\n
\n

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA),\u202fa clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b\/2 clinical trial of TN-201 gene therapy for MYBPC3<\/em>-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17.<\/p>\n

\n Conference Call and Webcast <\/strong>
\n
Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th<\/sup>, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register here<\/strong><\/a>. The live webcast will be available under the “Events\u201d section of the Investor Relations page of the Tenaya website at investors.tenayatherapeutics.com.<\/p>\n

An archived replay of the webcast will be available on Tenaya\u2019s website.<\/p>\n

\n About\u202fTenaya Therapeutics<\/strong>\u00a0
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya\u2019s pipeline includes TN-201, a gene therapy for MYBPC3<\/em>-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2<\/em>-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit\u202fwww.tenayatherapeutics.com<\/a>.\u00a0<\/p>\n

\n Tenaya Contacts<\/strong>\u00a0
Michelle Corral\u00a0
VP, Corporate Communications and Investor Relations\u00a0
IR@tenayathera.com<\/a>\u00a0<\/p>\n

\n Investors<\/strong>\u00a0
Anne-Marie Fields\u00a0
Precision AQ\u00a0\u00a0
annemarie.fields@precisionaq.com<\/a>\u00a0<\/p>\n

\n Media<\/strong>\u00a0
Wendy Ryan\u00a0
Ten\u202fBridge Communications\u00a0
wendy@tenbridgecommunications.com<\/a>\u00a0\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA),\u202fa clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b\/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17. Conference Call and Webcast Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register here. The live webcast will be … <\/p>\n

Continue reading “Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-795254","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA),\u202fa clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b\/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17. Conference Call and Webcast Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register here. The live webcast will be … Continue reading "Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-16T21:34:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDA4OSM2NjQwMDA4IzIyMDk0NDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\\\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024\",\"datePublished\":\"2024-12-16T21:34:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/\"},\"wordCount\":326,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDA4OSM2NjQwMDA4IzIyMDk0NDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/\",\"name\":\"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\\\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDA4OSM2NjQwMDA4IzIyMDk0NDY=\",\"datePublished\":\"2024-12-16T21:34:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDA4OSM2NjQwMDA4IzIyMDk0NDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDA4OSM2NjQwMDA4IzIyMDk0NDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\\\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/","og_locale":"en_US","og_type":"article","og_title":"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - Market Newsdesk","og_description":"Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA),\u202fa clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b\/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17. Conference Call and Webcast Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register here. The live webcast will be … Continue reading \"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-16T21:34:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDA4OSM2NjQwMDA4IzIyMDk0NDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024","datePublished":"2024-12-16T21:34:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/"},"wordCount":326,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDA4OSM2NjQwMDA4IzIyMDk0NDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/","name":"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDA4OSM2NjQwMDA4IzIyMDk0NDY=","datePublished":"2024-12-16T21:34:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDA4OSM2NjQwMDA4IzIyMDk0NDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDA4OSM2NjQwMDA4IzIyMDk0NDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-to-announce-initial-data-from-mypeak-1-phase-1b-2-clinical-trial-of-tn-201-gene-therapy-for-mybpc3-associated-hypertrophic-cardiomyopathy-on-tuesday-december-17-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b\/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=795254"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795254\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=795254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=795254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=795254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}